CA3136652A1 - Crystal forms of a pyridazinone trpc inhibitor - Google Patents

Crystal forms of a pyridazinone trpc inhibitor Download PDF

Info

Publication number
CA3136652A1
CA3136652A1 CA3136652A CA3136652A CA3136652A1 CA 3136652 A1 CA3136652 A1 CA 3136652A1 CA 3136652 A CA3136652 A CA 3136652A CA 3136652 A CA3136652 A CA 3136652A CA 3136652 A1 CA3136652 A1 CA 3136652A1
Authority
CA
Canada
Prior art keywords
crystalline form
disease
pharmaceutical composition
nephropathy
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136652A
Other languages
English (en)
French (fr)
Inventor
Yuejun GAO
Wenfeng Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goldfinch Bio Inc
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of CA3136652A1 publication Critical patent/CA3136652A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA3136652A 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor Pending CA3136652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081985 2019-04-10
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Publications (1)

Publication Number Publication Date
CA3136652A1 true CA3136652A1 (en) 2020-10-15

Family

ID=70482847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136652A Pending CA3136652A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Country Status (10)

Country Link
US (1) US12655132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953352A1 (cg-RX-API-DMAC7.html)
JP (2) JP7738482B2 (cg-RX-API-DMAC7.html)
CN (2) CN114502552B (cg-RX-API-DMAC7.html)
AU (2) AU2020272030C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018221A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136652A1 (cg-RX-API-DMAC7.html)
MA (1) MA55614A (cg-RX-API-DMAC7.html)
MX (2) MX2021012313A (cg-RX-API-DMAC7.html)
WO (2) WO2020206623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
LT3852533T (lt) * 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
JP7701559B2 (ja) * 2021-09-10 2025-07-01 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用
EP4470540A4 (en) * 2022-01-27 2025-06-11 Wuhan Createrna Science and Technology Co.,Ltd. USE OF A HETEROCYCLIC COMPOUND
CN119546303A (zh) * 2022-08-05 2025-02-28 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
US12435078B2 (en) * 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
LT3852533T (lt) 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도

Also Published As

Publication number Publication date
JP7738482B2 (ja) 2025-09-12
EP3953352A1 (en) 2022-02-16
WO2020206623A1 (en) 2020-10-15
BR112021018221A2 (pt) 2022-01-18
MX2021012313A (es) 2021-11-17
JP2022525759A (ja) 2022-05-19
MA55614A (fr) 2022-02-16
JP2026004294A (ja) 2026-01-14
MX2025006384A (es) 2025-07-01
AU2020272030C1 (en) 2026-05-07
US20220177455A1 (en) 2022-06-09
AU2020272030B2 (en) 2025-11-13
WO2020210639A1 (en) 2020-10-15
AU2026201003A1 (en) 2026-03-05
CN114502552A (zh) 2022-05-13
AU2020272030A1 (en) 2021-11-11
CN119264134A (zh) 2025-01-07
US12655132B2 (en) 2026-06-16
CN114502552B (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
AU2020272030C1 (en) Crystal forms of a pyridazinone TRPC inhibitor
JP7840031B2 (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
CN114040913B (zh) 哒嗪酮trpc5抑制剂的喷雾干燥制剂
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US20240091303A1 (en) Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
AU2019344928A1 (en) Pyridazinones and methods of use thereof
WO2026067059A1 (zh) Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途
JP2004534760A (ja) 腎線維症の治療
JP2930281B2 (ja) 皮膚疾患処置用薬剤
HK40122791A (en) Crystal forms of a pyridazinone trpc inhibitor
BR122025019562A2 (pt) Formas cristalinas de um inibidor de trpc de piridazinona, composição farmacêutica que as compreende e uso das mesmas
CN118043050A (zh) 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
KR20190091621A (ko) 벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
TW200522962A (en) Neutrophilia inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240409

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250305

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250305

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250911

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251223

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260303

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260706

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260710

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728